



**ECNP**

european college of  
neuropsychopharmacology

**ECNP**  
**Annual Report**  
**2012**



# ECNP

european college of  
neuropsychopharmacology



## Welcome

This Annual Report of the European College of Neuropsychopharmacology (ECNP) presents the numerous activities carried out in 2012 and explains how these activities have contributed to the fulfilment of ECNP's mission:

*“To advance the science of the brain, promote better treatment and enhance brain health”.*

2012 was a most notable event as we celebrated the **25<sup>th</sup> anniversary of ECNP**. In these 25 years ECNP has played a major role in the evolution of neuropsychopharmacology.

The characteristics that have defined ECNP for 25 years – its focus on high-quality research and education; excellent organisation; constructive, but independent engagement with industry; close cooperation with national European and international organisations – continue to shape its strategic direction and guide its future. The organisation is at the top of the tree in terms of both people and delivery and it has the highest integrity.

I am humbled by the dedicated volunteers, passionate members and supporters and committed staff who have invested and continue to invest their precious time. Your collective efforts continue to fuel our enthusiasm and motivation to fulfil ECNP's mission.

Joseph Zohar  
President ECNP

### INSIDE THIS ISSUE

Welcome .....	2
25 Years ECNP .....	3
Ethical Code of Conduct .....	4
New Version Bylaws .....	5
ECNP Review Board .....	5
J-MAP .....	6
Membership .....	7
Fellow Membership .....	7
ECNP Fellow Members .....	8
Membership Fees .....	9
ECNP Ambassadors .....	10
DepNet and Dementia Net ...	11
Medicines Chest .....	12
ECNP Certificate .....	13
ENP, e-news .....	14
Messages President.....	15
ECNP Matters .....	15
Social Media .....	15
ECNP Talks .....	16
ECNP Awards .....	17
ECNP Committees.....	18
Finance .....	25



# 25 Years ECNP



## THE FIRST QUARTER CENTURY



*“ECNP is my scientific home”*

*“For me, ECNP is the only truly committed interdisciplinary scientific organisation for mental health and mental disorders. There is no better place to exchange ideas and critically discuss progress”*

In March 1984, representatives of neuropsychopharmacological societies from across Europe sat down to dinner in Copenhagen to mark the 25th anniversary of the then Scandinavian Association of Psychopharmacology. European integration was in the air. The question was raised: might there be a case for a European structure, to give European neuropsychopharmacologists a platform to exchange and promote the region’s best research?

To follow-up on this idea, a meeting was held in Copenhagen in 1985. The rationale of a pan-European organisation was so powerful that it was decided to take it further: a European College of Neuropsychopharmacology (ECNP) would be founded. A Working Group was formed to plan the association’s inaugural scientific congress.

The inaugural congress was held in Brussels in 1987. Some 500 people attended from across Europe. ECNP was formally launched.

The College’s constitution came two years later in Gothenburgh—the same governance structure that serves ECNP today.

As well as the Congress, the College started a wide range of meetings, educational activities and scientific programmes. Together, these activities and initiatives make ECNP the largest non-institutional supporter of neuropsychopharmacological research and education in Europe.

The characteristics that have defined ECNP for 25 years—its focus on high-quality research and education; excellent organization; constructive, but independent engagement with industry; and close co-operation with national European and international organisations—continue to shape its strategic direction and guide its future.

For the last 25– years ECNP’s role in advancing the field has been critical; in the next 25 it will even be more so.



# Governance and Policies



## EXECUTIVE COMMITTEE 2010–2013

### Officers

Joseph Zohar, Israel, president  
Hans-Ulrich Wittchen, Germany, vice-president  
Guy Goodwin, United Kingdom, president-elect  
David Nutt, United Kingdom, past-president  
Sven Ove Ögren, Sweden, secretary  
Nicoletta Brunello, Italy, treasurer

### Councillors

Celso Arango, Spain  
Jaanus Harro, Estonia  
Gitte M. Knudsen, Denmark  
Mark J. Millan, France  
Wim van den Brink, The Netherlands  
Eduard Vieta, Spain

### Chair Scientific Programme Committee

Wim van den Brink, The Netherlands

### Editor-in-Chief European Neuropsychopharmacology

Michael Davidson, Israel

### Executive Director

Alexander Schubert, The Netherlands

## MISSION STATEMENT

The Executive Committee of ECNP has defined a mission statement which spells out its overall goals and primary objectives and provides a context in which the organisation's strategies are formulated: *“To advance the science of*

*the brain, promote better treatment and enhance brain health”.*

The policy plan, with the strategy for the coming years, can be found on:

[www.ecnp.eu](http://www.ecnp.eu).

## ETHICAL CODE OF CONDUCT

Mutual responsibility, a higher threshold of standards, and closer adherence to a code of conduct were all getting increased attention. To face these challenges, ECNP has established an Ethical Code of Conduct [link], which will give a well balanced direction for ECNP and its members how to behave and handle their activities and practical matters in real life. The document clearly recognises the need to uphold the highest ethical standards in research and the important of animal welfare issues. The Code of Conduct also stresses the importance of transparency in both the scientific and clinical domains which is in line with EU directives.

Members of ECNP were given the opportunity to comment

of the draft version of the Ethical Code of Conduct. At the General Assembly, held on 15 October 2012 in Vienna, Austria, the Ethical Code of Conduct was ratified by its members and put into use.

Allegations of violations of the Ethical Code of Conduct from any member will be reviewed by the President, Executive Director and the chair of the ECNP Review Board to determine whether the allegation is covered by the Code of Conduct. If the allegation is deemed to be so covered, the ECNP Review Board will consider written evidence from relevant parties and recommend to the Executive Committee whether expulsion should be considered or a lesser reaction such as a written warning.



# Governance and Policies

## NEW VERSION OF THE BYLAWS

The revision of the bylaws was a process that took several years. Lawyer from Swiss and The Netherlands were consulted. Members of ECNP were given the opportunity to comment on the draft bylaws.

At the General Assembly, held on 15 October 2012 in Vienna, Austria, the new version of the Bylaws [link] was ratified by its members and put into use.



### The major changes in the new bylaws are:

- ◆ Inclusion of e-voting
- ◆ Introduction of the ECNP Review Board, a committee that helps strengthen the quality of the college
- ◆ The legal states of the Executive Director and the ECNP Office
- ◆ The Code of Ethics

## ECNP REVIEW BOARD (ERB)

The ECNP Review Board (previously called “Scientific Committee”) was established in 2007. with the broad aim of overseeing the quality assurance of ECNP’s governance and that of its activities. It advises the Executive Committee on the independence and procedural rigor of all

ECNP projects and initiatives and monitors serious complaints concerning the College, ensuring an appropriate and timely response. In 2012 the rationale of the ECNP Review Board was made official by taking it up in the new ECNP Bylaws.

### *ECNP Review Board*

William Deakin, United Kingdom,  
*chair*

Laurence Lanfumey, France

Rafael Maldonado, Spain

Barbara Sahakian, United Kingdom

### The ERB ensures the ECNP organisation is

- ◆ Effective and focussed on its mission
  - ◆ Serving the interests of the membership
  - ◆ In a transparent, ethical and balanced way
- by
- ◆ Monitoring its governance, activities & strategy
  - ◆ Providing independent advice to Executive
  - ◆ Responding to complaints and disagreements



# Governance and Policies

## JUNIOR MEMBERS ADVISORY PANEL (J-MAP)

### JUNIOR MEMBER ADVISORY PANEL

Florian Riese, Switzerland, chair  
Covadonga M. Díaz-Caneja, Spain  
Kfir Feffer, Israel  
Rajna Knez, Croatia  
Kara Panetta, United Kingdom  
Olga Paravaya, Belarus

At the core of ECNP are a number of committees that are tasked with ensuring the college can effectively manage and best represent the needs of different members within its reach. With that in mind, the Junior Members Advisory Panel (J-MAP) has been assembled to make sure the college is responsive to the needs and wishes of its future members.

Comprised of a multinational team that includes graduates of the Workshop (to represent the pre-clinical multidisciplinary component) and the ECNP Schools, the panel will be rotated with fresh graduates on a regular basis to ensure that it can always remain very closely related to the needs of current juniors.

As chair of the panel, Florian Riese (Psychiatric University

Hospital Zurich, Switzerland) shared the aims of J-MAP, as well as touching upon the general initiatives that ECNP has in place to ensure a better and more inclusive future for its junior members. By organising places to network that have a more accessible atmosphere, J-MAP hopes the junior members will feel more comfortable, and make more connections that will encourage them to return to subsequent meetings and other activities.

They also hope to create an ongoing communication platform so that people who, for example, attended the schools and workshops can continue or maintain their professional relations to the other participants. To actually have exposure to senior members is a unique opportunity.



# ECNP Membership

Membership is the basis of the volunteer structure on which the College's public-interest activities depend. Annually, volunteers give hundreds of thousands of hours of their time. Without this commitment, and the remarkable investment of time and energy that comes with it, ECNP could not function.

## MEMBERSHIP NUMBERS

The total number of ECNP members increased in 2012. 105 Ordinary Members, 87 Associate Members and 7 Corresponding members joined the College, amounting to a total number of 1190 members. Seven members cancelled their membership.

The benefits of members who hadn't settled their payment by June 2012 were suspended. The Executive Committee decided to cancel the membership of those members who had arrears of more than one year.

## FELLOW MEMBERSHIP

In 2012 the College introduced a new membership category: Fellow Members. ECNP Fellows are appointed by the Executive Committee, in recognition of scientific distinction and notable contributions to the College. The role of the Fellow is to be actively engaged in the College, by sitting on committees, participating in ECNP Networks, lecturing at ECNP Seminars, etc. In addition, Fellows also play an integral part in the ECNP Certificate Programme by acting as mentor for

a Certificate student, assisting him/her in refining a suitable research topic, offering oversight in the execution of the project, advising in the preparation of the abstract and poster (for presentation at the ECNP Congress), and providing a point of contact at the congress. As a Certificate mentor, a Fellow should expect five to six contact points over the course of the two-year certificate cycle and a total time commitment of approximately 20 hours a year.

### Membership Committee

Gitte M. Knudsen, Denmark, *chair*  
Yechiel Levkovitz, Israel  
Hamish McAllister-Williams, United Kingdom  
Carmen Moreno, Spain  
Edwin Zvartau, Russia

### The following criteria are considered by the EC:

- ◆ Have attended at least three ECNP Congresses in the last five years
- ◆ Have presented at one ECNP Congress in the last ten years
- ◆ Be a reviewer in good standing for *European Neuropsychopharmacology*
- ◆ Have served on an ECNP Committee, or volunteered to serve
- ◆ Have been active in organising an ECNP event (Seminar, School, Mini-Symposium, etc.)
- ◆ Have supervised or mentored research projects before.



# *ECNP Membership*

## ECNP'S FELLOW MEMBERS

Carlo Altamura

Celso Arango

Francesc Artigas

David Baldwin

Anton Bernalov

Nicoletta Brunello

Eero Castrén

Roberto Cavallaro

Philip Cowen

Bill Deakin

Naomi Fineberg

Christine Gispen-de  
Wied

Lucianne Groenink

Guy Goodwin

Michel Hamon

Jaanus Harro

Andreas Heinz

Edith Holsboer-  
Trachsler

Cyril Höschl

Martien Kas

Siegfried Kasper

Gitte M. Knudsen

Laurence Lanfumey

Stephen Lawrie

Klaus-Peter Lesch

Michel Le Moal

Yechiel Levkovitz.

Astrid Linthorst

Paul J. Lucassen

Rafael Maldonado

Hamish McAllister-  
Williams

Andreas Meyer-  
Lindenberg

Mark Millan

Luisa Minghetti

Agneta Nordberg

David Nutt

Sven Ove Ögren.

Stefano Pallanti

Daniela Parolaro

Andrzej Pilc

Georgio Racagni

Andreas Reif

Janusz Rybakowski

Koen Schruers

Alessandro Serretti

David Slattery

Dan J. Stein

Alexandra Šulcová

Per Svenningsson

Jari Tiihonen

Wim van den Brink

Nic J.A. van der Wee

Eric Vermetten

Eduard Vieta

Ove Wiborg.

Hans-Ulrich Wittchen

Gil Zalsman

Joseph Zohar

Edwin Zvartau



# ECNP Membership

## REDUCED FEES FOR ASSOCIATE MEMBERS

In 2011 the College proposed to lower the membership fee for Associate Members from € 75 to € 50 and for Associate Members from countries with a developing economy (according to the World Bank

list) from € 50 to € 15. The proposal was ratified at the General Assembly meeting in September 2011 in Paris, France and came into effect on 1 January 2012.

**myECNP**

## MEMBERSHIP FEES 2012

<b>Ordinary Members</b>	<b>€ 120</b>
<b>Ordinary Members CDE *</b>	<b>€ 75</b>
<b>Associate Members</b>	<b>€ 50</b>
<b>Associate Members CDE</b>	<b>€ 15</b>
<b>Corresponding Members</b>	<b>€ 120</b>
<b>Corresponding Members CDE</b>	<b>€ 75</b>
<b>Retired Members</b>	<b>€ 75</b>

## OTHER NEWS

Next to direct online credit card payments, as of 2012 members can print out their invoice and receipt online,

and after the payment has been settled, their membership certificate.



# Ambassadors



Armen Melik-Pashayan, Armenia



Luchezar G. Hranov, Bulgaria



Miro Jakovljević, Croatia



Eka Chkonia, Georgia



Elmars Rancāns, Latvia



Robertas Bunevicius, Lithuania



Eugenia Sinita, Moldova



Joao Bessa, Portugal



Maria Ladea, Romania



Peter Morozov, Russian Federation



Gorica M. Djokic, Serbia



Rok Tavcar, Slovenia



Oguz Karamustafalioğlu, Turkey

## ECNP'S AMBASSADORS

ECNP was founded 25 years ago not just to foster and promote neuropsychopharmacological research in Europe, but to foster and promote it across Europe. This has been the guiding principle behind, amongst others, our Regional meetings, our Seminars and our emphasis on recruiting participants for the ECNP Congresses, Workshops and Schools from all corners of the region. The result is now a strong and vibrant support base, not just in Western Europe, but Eastern and Southern Europe as well.

In 2012 ECNP has launched an Ambassador's programme, to draw in countries even further afield, many of which lack the infrastructure to sustain a national society, and so have fallen outside the existing Advisory

Board of National Societies programme. For every country in Europe we plan to appoint an ECNP Ambassador. This person, a senior neuropsychopharmacologist in his or her region, will help to coordinate seminars and mini-symposia, to nominate [junior scientists](#) for the ECNP Schools and encourage application for the ECNP Workshop, and act as representative and point of contact for ECNP in his or her home country. Each ambassador will serve a term of two years.

The first meeting of the ECNP Ambassadors took place on 9 February 2012 in Sofia, Bulgaria.



# Public Outreach

## DEPNET AND DEMENTIA NET

To address the wider, public need for high-quality information, ECNP had launched patient websites on depression (DepNet.org) and dementia (Dementia.org). With DepNet already available in five European languages, and with more in the pipeline, the plan is to have most of Europe covered in the next couple of years. ECNP works in close cooperation with GAMIAN-Europe (Global Alliance of Mental Illness Advocacy Networks-Europe), a patient-driven pan-European organisation, which represents the interests of persons affected by mental illness and advocates for their rights. Its main objectives are: advocacy, information and education, anti-stigma and discrimination, pa-

tients' rights, co-operation, partnerships and capacity building.

In August 2012 ECNP and GAMIAN signed a letter of intent about collaboration for the operation and management of patient-oriented websites. This co-operation is in line with the College's intention to open a channel to the public, aimed at increasing the presence of disorders of the brain in the public dialogue. The two sites [www.depnet.org](http://www.depnet.org) and [www.dementianet.org](http://www.dementianet.org) will be operated on a European level by a steering committee composed of the College and GAMIAN, with similarly composed working groups at national level.



## ECNP GLOSSARY

In March 2012, the Executive Committee initiated a programme to mobilise ECNP members to contribute to a 'living' internet lexicon on neuropsychopharmacology by means of short, up-to-date articles on key terms and concepts in the field, written

by leading experts and providing general users with a high-quality, scientifically rigorous resource. The glossary will be hosted on the ECNP website, but also linked within the relevant Wikipedia articles and referenced in the External Links section.



# Public Outreach



David Nutt  
Past-President ECNP

## MEDICINES CHEST

The Medicines Chest, an initiative led by David Nutt, was initiated in 2011 to help clinical researchers gain access to pharmacological compounds held but unused by pharmaceutical companies.

Frequently, many potentially useful drugs are not exploited in clinical research for a variety of reasons: for example, they are poorly documented by companies in the event that their development is discontinued. In addition, clinical researchers are frequently unaware which agents are potentially available for research purposes, how to acquire such drugs, and the conditions under which they can be exploited.

ECNP hopes to help overcome such problems by acting as an intermediary between companies and researchers, and already several pharmaceutical companies have agreed to participate in this endeavour.

A list of drugs has been identified as useful research compounds and this list has been made available on the ECNP website [link]. This list is not exhaustive and ECNP would be pleased to hear of colleagues in the field which compounds would be worthwhile adding to the list.

## CLINICAL DATABASE

In 2012 an ECNP Clinical Database has been launched to collect patient data and make

them available to scientists working in the field.



# *Educational Programme*

## ECNP CERTIFICATE PROGRAMME

The ECNP Certificate is a new initiative that brings together all of the college's junior researcher programmes into a Europe-wide qualification backed by ECNP. At its core, the ECNP Certificate serves as recognition of the efforts and commitment of junior researchers in the field of applied and translational neuroscience with each candidate requiring to demonstrate a level of knowledge and skills that includes the ability to undertake either an original research project or effectively disseminate knowledge on the science and treatment of disorders of the brain by writing a scientific literature review or by organising an educational event.

Underpinning each certificate is one-to-one mentoring by an ECNP Fellow – experienced, senior members of the college from a number of wide-ranging backgrounds and international locations that are available to share their expertise and guidance, as well as giving feedback. Unlike PhD or Master's Thesis structures, mentors do not offer close supervision, and in fact it is preferred that they be located in a different country to their candidate, with quarterly (typically) catch-ups on the most substantive matters.

To be eligible for one of the 20 (approximately) certificate places in each rotation, candidates must have

participated in at least one ECNP Workshop, School or Seminar, or attended another ECNP-affiliated course. Once this is complete, an ECNP Fellow is then chosen under the guidance of the Certificate committee, and the project can begin.

Typically spanning six to twelve months, the project should culminate in a piece of original work or meaningful contribution that both the mentor and the Certificate Committee deem to be fit for accreditation and exhibition in poster format at the ECNP Congress. Once all these steps have been completed, the certificate itself will be bestowed upon candidates within the Keynote Session of the congress.


Although still in its early stages, the ECNP Certificate programme has already attracted candidates. The big challenge now is to get the word out, and to get people signed up.

The ECNP Certificate comes with no registration or tuition cost, and while it does not contain a grant, candidates can work remotely from their mentors, negating the need to travel, and once they complete the project they will be given free registration to exhibit their work at the ECNP Congress.





# Communication



## EUROPEAN NEUROPSYCHOPHARMACOLOGY

The journal of ECNP, *European Neuropsychopharmacology*, provides a medium for the prompt publication of articles in the field of neuropsychopharmacology. Its scope encompasses clinical and basic research relevant to the effects of centrally acting agents in its broadest sense.

The journal's impact factor has risen in 2012 to 4.595 (from 4.406 in 2011). The rejection rate has increased over time what brings it to 63% in 2012. The aim is 75-80%. Just over half of all submitted papers come from Europe. The publication time remained more or less the same although the aim still is to reduce it. Online articles continue to appear within 5 weeks. An increase is seen in online usage by institutions and in article downloads. This

year a Health Advance smartphone application for the journal was introduced. This app offers access to abstracts and the full text should be available later on.

Also the scientific community moves more and more to e-search and therefore it was decided in 2011 to head for a transition of the printed version of the journal to an e-version.

This transition came into effect on 1 July 2012. However those who would like to continue receiving the hard copy, could indicate so. Next to the 'green advantage' it enabled the College to provide open excess of the journal to colleagues from Eastern Europe almost for free. The journal is an excellent scientific leader and open access might open a route to scientific progression.

## E-NEWS

ECNP continued in 2012 with the monthly e-news messages, an effective way to keep you in touch with ECNP and its community. E-news reports the latest news on ECNP's upcoming meet-

ings, activities, new initiatives and developments as well as highlights from other organisations.



# Communication

## PRESIDENT'S MESSAGES

The President of ECNP, Joseph Zohar, initiated in 2010 the “President’s Messages”, monthly updates on ECNP activities with the intention to create an open and productive dialogue with colleagues in the field. These messages continued in 2011 and 2012. The plan is in accordance

with the aim to establish open more communication channels to the public, the plan for 2013 is to create a President’s blog, an online collaborative platform in which the public can submit their reactions on the President’s Messages and new ideas online.

## ECNP MATTERS


*ECNP Matters* is published twice or three times a year for the purpose of informing the ECNP community about important activities within the organisation. *ECNP Matters* contains practical, meeting-related information such as calls for papers, upcoming deadlines and reports on past meetings, contributions to the newsletter come from directly within

the community itself. These contributions range from articles written by distinguished scientists sharing their knowledge and experience, to up-and-coming young scientists with the potential to become prominent leaders in their field of expertise. In 2012 two issues of *ECNP Matters* were published.

## SOCIAL MEDIA

Social media has completely revolutionised the way we communicate with each other. It can also enable the organisation in sharing information in an informal, immediate and interactive way. Although social media can be intimidating for some, especially those with limited time and resources, its benefits outweigh

the effort required,. Therefore the College decided to step up its own social media activity, particularly on Facebook, Twitter and YouTube. You can ‘like’ ECNP at [www.facebook.com/myECNP](http://www.facebook.com/myECNP), [www.twitter.com/myECNP](http://www.twitter.com/myECNP) and [www.youtube.com/myECNP](http://www.youtube.com/myECNP).





# Communication



## TALKS OF THE MONTH

In an effort to bring high-quality information and insights about the brain and brain disorders to the informed and interested members of the public, ECNP has launched a new initiative called the 'Talk of the Month'. The 'Talk of the Month' is held in the form of a short video cast designed to summarise the key indi-

cations and developments in our field. Each invited speaker is an outstanding scientist in their specialised area of expertise and experienced in translating the science of neuropsychopharmacology into more general terms. The "Talk of the Month" videos are published on YouTube and the ECNP Website.

## Talk s recorded in 2012

Patrick McGorry	Early intervention and youth mental health	01 February 2012
René Kahn	Schizophrenia	01 March 2012
Robin Jacoby	Major depression in old age	01 April 2012
Trevor W. Robbins	Neuropsychopharmacology: bridging animal and human studies	01 May 2012
Andreas Meyer-Lindenburg	review of meta-analyses	01 June 2012
Richard Keefe	Cognitive impairment in schizophrenia	01 October 2012
Stefan Leucht	Neural mechanisms of risk for psychiatric disorders	01 November 2012
Til Wykes	Cognitive remediation and cognitive enhancement in schizophrenia	01 December 2012



# Awards

## ECNP LIFETIME ACHIEVEMENT AWARD

The ECNP Lifetime Achievement Award was established to recognise individuals who have made career-long and lasting contributions to the field of neuropsychopharmacology, at a national or international level. The award is presented biennially and


specifically recognised a lifelong dedication to and a significant impact on the field of neuropsychopharmacology. The award winner receives an unrestricted grant of EUR 20,000 and a commemorative gift.



## WINNER 2012

In 2012 the ECNP Lifetime Achievement Award was granted to Jules Angst, Emeritus Professor of Psychiatry at the University of Zurich (Switzerland) and Honorary Doctor of Heidelberg University, Germany. Jules Angst graduated in medicine from the University of Zurich in 1952 and trained in psychiatry under Manfred Bleuler at the Zurich Uni-

versity Psychiatric Hospital (the Burghölzli). In 1969 he was appointed Professor of Clinical Psychiatry and Director of the Burghölzli's newly-founded Research Department, retiring in 1994. He remains active full time in epidemiological and clinical research.





# Awards



## ECNP NEUROPSYCHOPHARMACOLOGY AWARD

The ECNP Neuropsychopharmacology Award recognises innovative and distinguished research achievements in neuropsychopharmacology and closely related disciplines. The award is granted each year, alternating between basic science and clinical research. The award winner receives an unrestricted prize of EUR 20,000, a commemorative gift, and is invited to present the award plenary lecture at the ECNP Congress. In addition, the award winner is asked to submit a review article for

publication in *European Neuropsychopharmacology* (to be submitted within six months after the award is granted).

In 2012 the ECNP Neuropsychopharmacology Award had a joint-recipient: Paul Harrison of the Department of Psychiatry of the University of Oxford, United Kingdom and Andreas Meyer-Lindenberg of the Central Institute of Mental Health, Mannheim, Germany.

## WINNER 2012—PAUL HARRISON



Professor Harrison has headed a research group investigating molecular, neuropathological, psychopharmacological and genetic aspects of psychosis. The group had a particular current interest in the neurobiology of schizophrenia risk genes, and utilised a range of experimental platforms and methods to investigate this question. He has published about 250 papers, several books and also has clinical, teaching and administrative roles. His

clinical work centres on treatment-resistant mood disorder and psychosis. He is a Deputy Editor for *Biological Psychiatry*, has served on various funding committees and chaired an NHS Research Ethics Committee. He has supervised 18 PhDs, and has been rated top lecturer on the Oxford psychiatry course for several years. He is currently President Elect of the British Association for Psychopharmacology.



# Awards

## WINNER 2012— ANDREAS MEYER-LINDENBERG

Prof. Dr. Meyer-Lindenberg is Director of the Central Institute of Mental Health, as well as the Medical Director of the Department of Psychiatry and Psychotherapy at the Institute, based in Mannheim, Germany and Professor and Chairman of Psychiatry and Psychotherapy at the University of Heidelberg in Heidelberg, Germany, and he is board certified in psychiatry, psychotherapy, and neurology. Prof. Dr. Meyer-Lindenberg is on the editorial board of a number of journals, such as *Nature*, *Biological Psychiatry*, *Psychiatry Research*:

*Neuroimaging*, and *Neuroimage*, and a reviewer for many others, including *Journal of Neuroscience*, *Molecular Psychiatry*, *Nature Medicine*, *Nature Reviews Neuroscience*, *Neuroimage*, *Neuroscience*, and *Neuropsychologia*. He is also the author of more than 200 peer-reviewed articles and book chapters. His research interests focus on using multimodal neuroimaging approaches to characterize functional brain circuits underlying the genetic risk for psychiatric disorders and cognitive dysfunction.



## ECNP MEDIA AWARD

In 2012 ECNP launched the 'ECNP Media Award', an award created in recognition of major contributions to destigmatising disorders of the brain in any medium, like journalism, literature, dance, film or theatre. The objective of this award is to inform and educate the European public about the personal and social impact of disorders of the brain. The award may be given for a specific product or project published, broadcast or posted online within Europe, in any European language. The winner of the first ECNP Media Award was the Science Media Centre based in London, United Kingdom. The Science Media Centre is a model

for how science can inform the public, facilitate public debate and enrich policy-making. Through its media relations activities, and especially its highly influential news briefings, the Centre has been extremely successful in spreading the knowledge and ensuring that science is made real and relevant for millions of people. The Science Media Centre manages to 'translate' the extraordinary advances being made every day in scientific research to the public in a direct and tangible way. The Science and Media Centre has made significant contributions to destigmatising disorders of the brain.





# ECNP Committees

## EXECUTIVE COMMITTEE

### *Officers*

Joseph Zohar, Israel, *president*  
Hans-Ulrich Wittchen, Germany, *vice-president*  
Guy Goodwin, United Kingdom, *president-elect*  
David Nutt, United Kingdom, *past-president*  
Sven Ove Ögren, Sweden, *secretary*  
Nicoletta Brunello, Italy, *treasurer*

### *Chair Scientific Programme Committee*

Wim van den Brink, The Netherlands

### *Editor-in-Chief European Neuropsychopharmacology*

Michael Davidson, Israel

### *Executive Director*

Alexander Schubert, The Netherlands

### *Councillors*

Celso Arango, Spain  
Jaanus Harro, Estonia  
Gitte M. Knudsen, Denmark  
Mark J. Millan, France  
Wim van den Brink, The Netherlands  
Eduard Vieta, Spain





# ECNP Committees

## INDEPENDENT COMMITTEES

### Scientific Programme Committee 25<sup>th</sup> ECNP Congress

Wim van den Brink, The Netherlands, *chair*  
Celso Arango, Spain, *chair Educational Committee*  
Michael Davidson, Israel, *editor-in-chief journal ENP*  
Eero Castrén, Finland  
Damiaan Denys, The Netherlands  
Antonio Gil-Nagel, Spain  
Michel Hamon, France  
Michal Hrdlicka, Czech Republic  
Zoltán Janka, Hungary  
Hans Lassmann, Austria  
Astrid Linthorst, United Kingdom  
Andreas Meyer-Lindenberg, Germany  
Wolfgang Oertel, Germany  
Isabella Pacchiarotti, Spain  
Marie-Claude Potier, France  
Rainer Rupprecht, Germany  
Joanna Strosznajder, Poland  
Louk Vanderschuren, The Netherlands

### Nominating Committee

David Nutt, United Kingdom, *chair*  
Guy Goodwin, United Kingdom  
Cyril Höschl, Czech Republic  
Marian Joëls, The Netherlands  
Laurence Lanfumey, France  
Sven Ove Ögren, Sweden  
Joseph Zohar, Israel

### ECNP Review Board

William Deakin, United Kingdom, *chair*  
Laurence Lanfumey, France  
Rafael Maldonado, Spain  
Barbara Sahakian, United Kingdom



# ECNP Committees

## Award Committee

Julien Mendlewicz, Belgium, *chair*  
Kaj Blennow, Sweden  
Philip J. Cowen, United Kingdom  
Guy Goodwin, United Kingdom  
Andreas Heinz, Germany  
Michel Le Moal, France  
Georgio Racagni, Italy  
Jari Tiihonen, Finland

## Communication Committee

Hans-Ulrich Wittchen, Germany, *chair*  
Guy Goodwin, United Kingdom  
Jaanus Harro, Estonia  
Michel Hamon, France  
David Nutt, United Kingdom  
Joseph Zohar, Israel,

Advisor:

Michael Davidson, Israel

## Certificate Committee

Celso Arango, Spain  
Naomi Fineberg, United Kingdom  
Koen Schruers, The Netherlands  
Alexander Schubert, The Netherlands  
Joseph Zohar, Israel

## Consultation Committee

David Nutt, United Kingdom, *chair*  
Celso Arango, Spain  
David Baldwin, United Kingdom  
Karl Broich, Germany  
Christine C. Gispen-de Wied, The Netherlands  
Guy Goodwin, United Kingdom  
Maria Isaac, United Kingdom  
Jim van Os, The Netherlands  
Sven Ove Ögren, Sweden

Co-opt

Michael Davidson, Israel

## Educational Committee

Celso Arango, Spain, *chair*  
Naomi Fineberg, United Kingdom  
Edith Holsboer-Trachsler, Switzerland  
Stefano Pallanti, Italy  
Walter Pirker, Austria  
Florian Riese, Switzerland  
Janusz H. Rybakowski, Poland  
Koen Schruers, The Netherlands  
Gil Zalsman, Israel  
Joseph Zohar, Israel



# ECNP Committees

## Junior Members Advisory Panel

Florian Riese, Switzerland, *chair*  
Covadonga M. Díaz-Caneja, Spain  
Kfir Feffer, Israel  
Rajna Knez, Croatia  
Kara Panetta, United Kingdom  
Olga Paravaya, Belarus

## Membership Committee

Gitte M. Knudsen, Denmark, *chair*  
Yechiel Levkovitz, Israel  
Hamish McAllister-Williams, United Kingdom  
Carmen Moreno, Spain  
Edwin Zvartau, Russia

## Workshop Committee

Mark J. Millan, France, *chair*  
Michel Hamon, France  
Jaanus Harro, Estonia  
Martien Kas, The Netherlands  
Astrid Linthorst, United Kingdom  
Andreas Meyer-Lindenberg, Germany  
Andreas Reif, Germany  
Alessandro Serretti, Italy  
David A. Slattery, Germany  
Per Svenningsson, Sweden  
Eduard Vieta, Spain

## School Committee

Guy Goodwin, United Kingdom, *chair*  
Celso Arango, Spain  
Robin Jacoby, United Kingdom  
Joseph Zohar, Israel  
Alessandro Zuddas, Italy



# ECNP committees

## SCIENTIFIC ADVISORY PANELS

### **Addiction**

Julio Bobes, Spain  
Jocelyne Caboche, France  
Karen Ersche, United Kingdom  
Gabriele Fischer, Austria  
Johan Franck, Sweden  
Philip Gorwood, France  
Anne Lingford-Hughes, United Kingdom  
Marcus Munafó, United Kingdom  
Florence Noble, France  
Rainer Spanagel, Germany

### **Anxiety disorders, OCD, stress related disorders and treatment**

David Baldwin, United Kingdom  
Johan A. den Boer, The Netherlands  
Damiaan Denys, The Netherlands  
Dave Finn, Ireland  
Andrew Gloster, Germany  
Astrid Linthorst, United Kingdom  
Raymond Mongeau, France  
Stefano Pallanti, Italy

### **Basic and clinical neuroscience**

Anton Bespalov, Germany  
Eero Castrén, Finland  
Kevin Fone, United Kingdom  
Andreas Heinz, Germany

Martien Kas, The Netherlands  
Klaus-Peter Lesch, Germany  
Isabelle Mansuy, Switzerland  
Oscar Marín, Spain  
Anabel Martinez-Aran, Spain  
Jean Luc Martinot, France  
Inga Neumann, Germany  
Nick Ramsey, The Netherlands  
Oliver Stiedl, The Netherlands

### **Child and adolescent disorders treatment**

Jan Buitelaar, The Netherlands  
Josefina Castro-Fornieles, Spain  
Michal Hrdlicka, Czech Republic  
Rainald Mössner, Germany  
Mara Parellada, Spain  
Marie-Claude Potier, France  
Abraham Weizman, Israel  
Alessandro Zuddas, Italy

### **Dementia and neurological disorders**

Christoph Baumgartner, Austria  
Jan Booij, The Netherlands  
Christoph Hock, Switzerland  
Hans Lassmann, Austria  
Jean Mariani, France  
Walter Pirker, Austria  
Juha Rinne, Finland  
Frederic Saudou, France  
Michael Schüpbach, Switzerland

### **Mood disorders and treatment**

Ian Anderson, United Kingdom  
Catherine Belzung, France  
Francesc Colom, Spain  
Catherine Harmer, United Kingdom  
Erkki Isometsä, Finland  
Marion Leboyer, France  
Arne Mørk, Denmark  
Mariusz Papp, Poland  
Rainer Rupprecht, Germany  
Alessandro Serretti, Italy  
Daniel Souery, Belgium  
Per Svenningsson, Sweden  
Aysegül Yildiz, Turkey

### **Psychotic disorders and treatment**

Istvan Bitter, Hungary  
Ronan Depoortere, France  
Filippo Drago, Italy  
Liewe de Haan, The Netherlands  
Andreas Meyer-Lindenberg, Germany  
Paula Moran, United Kingdom  
Dieter Naber, Germany  
Joseph Peuskens, Belgium  
Dan Rujescu, Germany  
Janusz Rybakowski, Poland  
John Waddington, Ireland



# Finance

## REIMBURSEMENT COMMITTEE MEMBERS

### **Secretarial Assistance**

The President of the Executive Committee receives € 15,000 for secretarial assistance.

The past-president, president-elect, vice-president, secretary and treasurer all receive € 4,000 for secretarial assistance.

### **Reimbursement small expenses**

All members of the Executive Committee receive a yearly reimbursement of € 1,500. This amount should cover their expenses for ground transportation, lunch, dinner, drinks etc.

The members of the Executive Committee receive the reimbursements as stated above and do not receive any remuneration for their services.



# Finance

## BALANCE SHEET AS AT 31 DECEMBER 2012 (2011)

	31-12-2012	31-12-2012
	CHF	€
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
<b>Accounts receivable</b>		
Debtors	10.711	8.878
Amounts owed by foundation Stichting Buro ECNP	952.340	789.341
Amounts owed by ECNP Research and Scholarship Foundation	2.197.459	1.821.350
Taxes	374.649	310.526
Other accounts receivable	504.217	417.917
	<u>4.039.376</u>	<u>3.348.012</u>
<b>Securities</b>	13.485.300	11.177.205
<b>Bank deposits</b>	81.115	67.232
	<u><u>17.605.791</u></u>	<u><u>14.592.449</u></u>



# Finance

## BALANCE SHEET AS AT 31 DECEMBER 2012 (2011)

	31-12-2012	31-12-2011
	CHF	€
<b>LIABILITIES</b>		
<b>Equity</b>		
Brought forward from last year	16.376.502	13.573.560
Result 2012 (2011)	1.084.023	898.484
	<u>17.460.525</u>	<u>14.472.044</u>
<b>Current liabilities</b>		
Trade creditors	10.548	8.743
Other liabilities	134.719	111.662
	<u>145.267</u>	<u>120.405</u>
	<u><u>17.605.792</u></u>	<u><u>14.592.449</u></u>



# Finance

## PROFIT AND LOSS ACCOUNT 2012 (2011)

	2012	2012
	CHF	€
<b>I N C O M E</b>		
<b>Membership fees</b>		
Personal membership fees	116.970	96.950
<b>Donations</b>		
Unrestricted grant	447.209	370.666
<b>Interest and similar income</b>		
Royalties Elsevier	57.848	47.947
Interest bank	14.850	12.308
Interest on bonds	248.531	205.993
Dividend on shares	58.941	48.853
Adjustment shares and bonds to market value	(35.909)	(29.763)
Realized results on securities	905.251	750.312
	<u>1.249.512</u>	<u>1.035.650</u>
<b>TOTAL INCOME (balance forward)</b>	<b>1.813.691</b>	<b>1.503.266</b>



# Finance

	2012	2012
	CHF	€
<b>TOTAL INCOME (balance forward)</b>	1.813.691	1.503.266
<b>EXPENSES</b>		
<b>Administration</b>		
Recharge by Stichting Buro ECNP	199.206	165.111
<b>Other expenses</b>		
Audit fee and consulting charges	121.295	100.535
Meeting and travel expenses	112.547	93.284
Secretarial support EC-officers	65.151	54.000
Provision bad debt	7.299	6.050
Membership fees to other organisations	31.383	26.012
25-years ECNP	33.716	27.945
General college expenses	6.914	5.731
Subtotal	378.305	313.557
<b>Publication</b>		
European Neuropsychopharmacology	80.102	66.392
ECNP Matters	6.043	5.009
Depression Net	23.476	19.458
ECNP Certificate	11.739	9.730
E-News	8.962	7.428
Talk of the Month	4.703	3.898
Wikipedia	5.429	4.500
Material	6.752	5.596
<b>TOTAL EXPENSES (balance forward)</b>	724.717	600.679



# Finance

	2012	2012
	CHF	€
<b>TOTAL EXPENSES (balance forward)</b>	724.717	600.679
<b>Interest and similar charges</b>		
Account commission costs	1.926	1.596
Bank charges	3.025	2.507
Subtotal	<u>4.951</u>	<u>4.103</u>
<b>TOTAL EXPENSES</b>	729.668	604.782
<b>NET RESULT</b>	<u><u>1.084.023</u></u>	<u><u>898.484</u></u>



# Finance

## 3.4 EXPLANATORY NOTES TO THE BALANCE SHEET AS AT 31 DECEMBER 2012 (2011)

	31-12-2012		31-12-2011	
	CHF	€	CHF	€
<b>CURRENT ASSETS</b>				
<b>Accounts receivable</b>				
<b>Debtors</b>				
Personal membership fees	28.013	23.219	11.700	
Less: Provision for bad debtors	(17.302)	(14.341)	(11.700)	
	<u>10.711</u>	<u>8.878</u>	<u>-</u>	
<b>Taxes</b>				
Corporate income tax 2009	344.868	285.842	-	
Value added tax	29.781	24.684	-	
	<u>374.649</u>	<u>310.526</u>	<u>-</u>	
<b>Other accounts receivable</b>				
Unrestricted grant to be received	301.625	250.000	-	
Reimbursement receivable	57.848	47.947	63.656	
Dividend shares receivable	-	-	22.661	
Interest bank-savings	157	130	3.798	
Interest bonds	144.587	119.840	-	
	<u>504.217</u>	<u>417.917</u>	<u>90.115</u>	



# Finance

	31-12-2012		31-12-2011	
	CHF	€	€	€
<b>Securities</b>				
Bonds	8.506.679	7.050.706	974.180	
Shares	4.978.621	4.126.499	8.679.413	
	<u>13.485.300</u>	<u>11.177.205</u>	<u>9.653.593</u>	

As per 31 December 2012 the market value of the shares and bonds amounts € 11,295,744

For further specification of securities we refer to annex 4.1 of this report.

## Bank deposits

F. van Lanschot Bankiers, current-account	43.480	36.038	274.627
F. van Lanschot Bankiers, deposit	3.881	3.217	1.122.372
ING Bank N.V., deposit	33.666	27.904	-
ING Bank N.V., deposit	60	50	-
ING Bank N.V., current account	28	23	-
	<u>81.115</u>	<u>67.232</u>	<u>1.396.999</u>

## Current liabilities

### Other liabilities

Legal advice	60.718	50.326	-
Recharge costs Stichting Buro ECNP	59.339	49.183	-
Accrued audit fee	8.023	6.650	6.104
Bank charges	72	60	13.121
Other liabilities	6.567	5.443	-
	<u>134.719</u>	<u>111.662</u>	<u>19.225</u>



# *Information*

## **General Information**

The European College of Neuropsychopharmacology (ECNP) is a public-interest-serving entity.

Address:

European College of Neuropsychopharmacology

Bolognalaan 28

3584 CJ Utrecht

Tel: 0031 88 7569555

E-mail: [secretariat@ecnp.eu](mailto:secretariat@ecnp.eu) Website: [www.ecnp.eu](http://www.ecnp.eu)

RSIN: 823523974